Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL269743 | 0.88 | — | — | |
| SCHEMBL4510709 | 0.79 | MEN1 (0.44) | TSHRTHRBMEN1KMT2ANAAA | |
| SCHEMBL6176135 | 0.79 | TSHR (0.40) | TSHRTHRBMEN1KMT2ANAAA | |
| SCHEMBL4512993 | 0.79 | MEN1 (0.44) | TSHRTHRBMEN1KMT2ANAAA | |
| SCHEMBL9205665 | 0.77 | OPRM1 (0.42) | TSHRTHRBMEN1KMT2ANAAA | |
| SCHEMBL9205449 | 0.77 | DNM1 (0.44) | TSHRTHRBMEN1KMT2ANAAA | |
| SCHEMBL9209437 | 0.77 | OPRM1 (0.42) | TSHRTHRBMEN1KMT2ANAAA | |
| SCHEMBL9203784 | 0.77 | OPRM1 (0.42) | TSHRTHRBMEN1KMT2ANAAA | |
| SCHEMBL4522986 | 0.76 | — | — | |
| SCHEMBL6177787 | 0.76 | NAAA (0.36) | TSHRTHRBMEN1KMT2ANAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3835367-A1 | ADDITIVE COMPOSITION, FLAME-RETARDANT SYNTHETIC RESIN COMPOSITION CONTAINING SAME, AND MOLDED ARTICLE THEREOF | ADEKA CORPORATION (JP) | 2021-06-16 | — | — | EP | disclosed |
| CN-112368339-A | Additive composition, flame-retardant synthetic resin composition containing same, and molded article thereof | 株式会社ADEKA | 2021-02-12 | — | — | CN | disclosed |
| WO-2020032210-A1 | ADDITIVE COMPOSITION, FLAME-RETARDANT SYNTHETIC RESIN COMPOSITION CONTAINING SAME, AND MOLDED ARTICLE THEREOF | 株式会社ADEKA | 2020-02-13 | — | — | WO | disclosed |
| EP-0945445-B9 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2005-12-28 | — | — | EP | disclosed |
| US-20050148634-A1 | 1-N-Aminobenzimidazole derivatives | ZERIA PHARMACEUTICAL CO., LTD (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-0945445-B1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-6239131-B1 | WHICH HAVE GASTRIN AND/OR CCK-B (CHOLECYSTOKININ-B) RECEPTOR ANTAGONISM, USEFUL AS REMEDIES FOR GASTRIC ULCER AND GASTROINTESTINAL MOVEMENT DISORDER. | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-29 | — | — | US | disclosed |
| EP-0945445-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
| EP-0641207-A4 | ENANTIOMERIC CYNEMICIN ANALOGS, PREPARATION AND USE THEREOF. | SCRIPPS RESEARCH INST (US) | 1996-08-14 | — | — | EP | disclosed |
| US-5527805-A | DNA-CLEAVING, CYTOTOXIC AND ANTI-TUMOR COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1996-06-18 | — | — | US | disclosed |
| US-H1487-H | Antitumor agents; treatment of ovarian, breast and other cancers | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-09-05 | — | — | US | disclosed |
| EP-0641207-A1 | ENANTIOMERIC CYNEMICIN ANALOGS, PREPARATION AND USE THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 1995-03-08 | — | — | EP | disclosed |
| US-5281710-A | Antibiotics or antitumor agents | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-01-25 | — | — | US | disclosed |
| US-5276159-A | Antitumor | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-01-04 | — | — | US | disclosed |
| WO-1993023046-A1 | ENANTIOMERIC CYNEMICIN ANALOGS, PREPARATION AND USE THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 1993-11-25 | — | — | WO | disclosed |
| EP-0569281-A1 | Benzoate derivatives of taxol | Bristol-Myers Squibb Company (US) | 1993-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148634-A1 | 1-N-Aminobenzimidazole derivatives | CYP1B1, CYP2E1, CYP1A1 | TSHR 3190/4885THRB 1921/4885MEN1 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.